Prysm Interactive LPD Boards Are Changing Boardrooms

At InfoComm 2018 Prysm stood out from the barrage of vendors lining the exhibit halls. MarketScale sat down with Vice President of Marketing Hannah Grap, to discuss Prysm’s latest project and the advancements they’ve made in the digital signage industry.

The showcase this year for Prysm revolved around its brand new 6K resolution LPD video series wall. InfoComm marked the first trade show Prysm made this product available for the public to see. Two aspects of this wall set it apart from the competition—the bezel-free technology eliminating unwanted seams within the wall and its natively touch enabled screen, giving the customer a new, high definition, and interactive experience.

High valued collaboration spaces are some of the most sought out applications for this wall according to Grap. From boardrooms to conference centers, this wall can be used to really drive sales and impress clients in the process, emphasizing “They want to have that wow factor.”

Grap lauds the value this digital wall can have for retail solutions as well. Referencing a partnership with Under Armor, Grap highlighted how important the “fun” aspect of interactive digital signage is going to be for industries throughout.

“UA uses LPD in their recruitment centers, so when they recruit new athletes they’re able to deliver a very nice up-close interactive experience,” she said.

When it comes to traditional brick and mortar, amplifying the customer experience often delivers the best results, which is why Grap sees many other signage companies starting to catch up.

“Getting that wow factor with the interactivity is becoming more of a requirement than something just to have,” she said.

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More